Tata Consultancy Services has launched TCS ADD AgentHub, an enterprise-ready agentic AI platform designed to automate and support workflows across clinical development and pharmacovigilance, as artificial intelligence gains ground in the life sciences industry.
The platform uses role-based AI agents that can perform tasks across drug development workflows while operating within defined governance and oversight frameworks. TCS is positioning AgentHub as a way for pharmaceutical companies to introduce agentic AI into regulated processes without removing human accountability from critical decisions.
AgentHub is designed around what TCS calls a "Human + AI Operating Model." Under the approach, AI agents can handle defined operational tasks while human professionals retain control over decisions, governance and regulatory responsibilities.
The platform covers multiple clinical and drug safety functions, including Individual Case Safety Report intake and processing, protocol digitisation, medical monitoring and Study Data Tabulation Model transformation.
TCS said pharmaceutical companies can select AI agents from a scalable catalogue and deploy them according to specific operational requirements. The system is also designed to integrate with existing clinical technology environments, allowing companies to introduce agents progressively rather than replace their existing infrastructure.
According to TCS, AgentHub can deliver efficiency improvements of up to 40% in clinical data management and reduce clinical study build effort by up to 30% through metadata-driven automation.
The company also claims the platform can deliver up to 30% cost savings in safety case processing and reduce quality control efforts by as much as 50%. These figures are TCS-reported outcomes and have not been independently benchmarked in the announcement.
The emphasis on governance reflects the regulatory requirements surrounding pharmaceutical development, where clinical and patient safety processes require traceability, documentation and human oversight.
Unlike conventional generative AI tools that primarily generate or summarise content in response to prompts, agentic AI systems are designed to perform multi-step tasks, interact with tools and coordinate actions towards a defined objective.
For pharmaceutical companies, this can potentially extend AI from assisting individual employees to handling parts of larger operational workflows. However, the use of AI in regulated environments also places requirements around auditability, accountability and the ability to supervise automated decisions.
Debashis Ghosh, President, Life Sciences and Healthcare at TCS, said the platform is intended to support proactive, scalable and audit-ready operations across drug development and patient safety.
AgentHub also builds on TCS's existing ADD portfolio for life sciences. The company's ADD Safety platform already uses agentic AI for pharmacovigilance workflows, with TCS stating that the system processes more than one million safety cases annually.
The launch comes as pharmaceutical companies increase their use of AI across clinical trials, drug safety, medical monitoring and research processes. TCS has previously said its life sciences work includes generative AI projects covering literature searches, patient insights, safety case processing and medical monitoring.
With AgentHub, TCS is extending that work towards AI agents designed to operate across multiple stages of clinical development and pharmacovigilance, while keeping human oversight and regulatory controls within the workflow.
Disclaimer: This article may include information derived from interviews, press releases, public statements, research, company communications and other publicly available or third-party sources. Such material may be summarised, paraphrased or contextualised for journalistic and editorial purposes. All rights in third-party content remain with their respective owners.
Related Articles
